Literature DB >> 7301281

Prednisolone plasma levels after oral administration of Prednimustine. Comparison with levels obtained after administration of an equimolar dose of prednisolone.

A Sayed, W V Hove, A Vermeulen.   

Abstract

After oral administration of 100 mg Prednimustine to patients with metastatic breast carcinoma, prednisolone levels and the area under the plasma concentration-time curve between 2 and 24 h are approximately half of those obtained after the administration of an equivalent dose of prednisolone. As previous studies have reported up to 55% of unchanged Prednimustine in feces. It is suggested that prednisolone plasma levels are as good a parameter of Prednimustine absorption and bioavailability as chlorambucil levels, Prednimustine itself having never been detected in plasma. Whether Prednimustine is hydrolyzed in the intestine before absorption or rapidly taken up by the tissues and hydrolyzed in situ after absorption is unclear at the moment. Myelosuppressive effects of Prednimustine correlated very well with maximal prednisolone levels, emphasizing the value of prednisolone level measurements.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7301281     DOI: 10.1159/000225586

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay.

Authors:  M M Oppitz; E Musch; M Malek; H P Rüb; G E von Unruh; U Loos; B Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro.

Authors:  E Musch; M Malek; J Peter-Katalinic; H Egge; H Rink; B Lathan; E Riedel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients.

Authors:  L Bastholt; C J Johansson; P Pfeiffer; L Svensson; S A Johansson; P O Gunnarsson; H Mouridsen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.